PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31195162-7	2020	Rivaroxaban, but not other NOACs, was associated with an increased risk for major GIB (RR from randomized controlled trials, 1.39; 95% CI, 1.17-1.65 and aHR from real-world studies, 1.14; 95% CI, 1.04-1.23; Pinteraction = .06).	Rivaroxaban	0-11	aryl hydrocarbon receptor	Homo sapiens	153-156	
24926732-11	2014	Patients on rivaroxaban had a significantly better rate of persistence (aHR: 0.63, 95% CI 0.59-0.68) and lower rate of discontinuation (aHR: 0.54, 95% CI 0.49-0.58) compared to warfarin recipients.	Rivaroxaban	12-23	aryl hydrocarbon receptor	Homo sapiens	72-75	
24926732-11	2014	Patients on rivaroxaban had a significantly better rate of persistence (aHR: 0.63, 95% CI 0.59-0.68) and lower rate of discontinuation (aHR: 0.54, 95% CI 0.49-0.58) compared to warfarin recipients.	Rivaroxaban	12-23	aryl hydrocarbon receptor	Homo sapiens	136-139